<DOC>
	<DOCNO>NCT01978938</DOCNO>
	<brief_summary>This Phase 3 , Randomized , Double-Blind , Double-Dummy , Multicenter , Prospective Study Assess Efficacy Safety Eravacycline Compared Levofloxacin Complicated Urinary Tract Infections ( cUTI )</brief_summary>
	<brief_title>Efficacy Safety Study Eravacycline Compared With Levofloxacin Complicated Urinary Tract Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>1 . Male female subject either : a. Pyelonephritis normal urinary tract anatomy ( 30 % total population ) , OR b. cUTI least one follow condition associate risk develop cUTI : i. Indwelling urinary catheter ii . Urinary retention ( approximately 100 mL residual urine voiding ) iii . Neurogenic bladder iv . Partial obstructive uropathy ( eg , nephrolithiasis , bladder stone , ureteral stricture ) v. Azotemia renal origin ( CHF volume relate ) serum BUN elevate ( &gt; 20 mg/dL ) AND serum BUN : creatinine ratio &lt; 15 vi . Surgically modify abnormal urinary tract anatomy ( eg , bladder diverticulum , redundant urine collection system , etc . ) EXCEPT surgery within last month 1 . Concurrent use nonstudy antibacterial drug therapy would potential effect outcome evaluation subject cUTI , include : 1 . Subjects history levofloxacinresistant urinary tract infection 2 . Likely receive ongoing antibacterial drug prophylaxis prior LPT visit ( eg , subject vesiculoureteral reflux )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>